Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
A 36-year-old man had decreased vision as well as advanced proliferative diabetic retinopathy and macular edema (Figure 1 and Figure 2). Visual acuity was 20/100 OD. After a lengthy informed consent discussion, he elected to be treated with 1.25 mg of intravitreal bevacizumab (Avastin; Genentech, Inc, South San Francisco, Calif) in the right eye and to defer immediate panretinal photocoagulation.1,2 When preparing to do the panretinal photocoagulation 8 days later, complete absence of neovascularization of the optic disc was noted (Figure 3 and Figure 4), the patient's visual acuity was 20/40, and the laser was deferred.
Friedlander SM, Welch RM. Vanishing Disc Neovascularization Following Intravitreal Bevacizumab (Avastin) Injection. Arch Ophthalmol. 2006;124(9):1365. doi:10.1001/archopht.124.9.1365